Hosted on MSN19d
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass itSince Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes ... but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.
(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes ... but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results